Trpv6 channel targeting using monoclonal antibody induces prostate cancer cell apoptosis and tumor regression - Centre Oscar Lambret
Article Dans Une Revue Cell Death and Disease Année : 2024

Trpv6 channel targeting using monoclonal antibody induces prostate cancer cell apoptosis and tumor regression

Alexandre Barras

Résumé

Abstract TRPV6 calcium channel is a prospective target in prostate cancer (PCa) since it is not expressed in healthy prostate while its expression increases during cancer progression. Despite the role of TRPV6 in PCa cell survival and apoptotic resistance has been already established, no reliable tool to target TRPV6 channel in vivo and thus to reduce tumor burden is known to date. Here we report the generation of mouse monoclonal antibody mAb82 raised against extracellular epitope of the pore region of the channel. mAb82 inhibited TRPV6 currents by 90% at 24 µg/ml in a dose-dependent manner while decreasing store-operated calcium entry to 56% at only 2.4 µg/ml. mAb82 decreased PCa survival rate in vitro by 71% at 12 µg/ml via inducing cell death through the apoptosis cascade via activation of the protease calpain, following bax activation, mitochondria enlargement, and loss of cristae, Cyt C release, pro-caspase 9 cleavage with the subsequent activation of caspases 3/7. In vivo, mice bearing either PC3M$^{trpv6+/+}$ or PC3M$^{trpv6+/-}$ +pTRPV6 tumors were successfully treated with mAb82 at the dose as low as 100 µg/kg resulting in a significant reduction tumor growth by 31% and 90%, respectively. The survival rate was markedly improved by 3.5 times in mice treated with mAb82 in PC3M$^{trpv6+/+}$ tumor group and completely restored in PC3M$^{trpv6-/-}$ +pTRPV6 tumor group. mAb82 showed a TRPV6-expression dependent organ distribution and virtually no toxicity in the same way as mAbAU1, a control antibody of the same Ig2a isotype. Overall, our data demonstrate for the first time the use of an anti-TRPV6 monoclonal antibody in vitro and in vivo in the treatment of the TRPV6-expressing PCa tumors.
Fichier principal
Vignette du fichier
Haustrate_2024_s41419-024-06809-0.pdf (5.54 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
licence

Dates et versions

hal-04665305 , version 1 (31-07-2024)

Licence

Identifiants

Citer

Aurélien Haustrate, Clément Cordier, George Shapovalov, Adriana Mihalache, Emilie Desruelles, et al.. Trpv6 channel targeting using monoclonal antibody induces prostate cancer cell apoptosis and tumor regression. Cell Death and Disease, 2024, 15 (6), pp.419. ⟨10.1038/s41419-024-06809-0⟩. ⟨hal-04665305⟩
85 Consultations
16 Téléchargements

Altmetric

Partager

More